PT2415771E - Derivado de indolizina e sua utilização para fins médicos - Google Patents
Derivado de indolizina e sua utilização para fins médicosInfo
- Publication number
- PT2415771E PT2415771E PT107587131T PT10758713T PT2415771E PT 2415771 E PT2415771 E PT 2415771E PT 107587131 T PT107587131 T PT 107587131T PT 10758713 T PT10758713 T PT 10758713T PT 2415771 E PT2415771 E PT 2415771E
- Authority
- PT
- Portugal
- Prior art keywords
- fluorine
- prevention
- agents
- treatment
- hydroxy group
- Prior art date
Links
- 125000003406 indolizinyl group Chemical class C=1(C=CN2C=CC=CC12)* 0.000 title abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 239000011737 fluorine Substances 0.000 abstract 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 229940116269 uric acid Drugs 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 108010093894 Xanthine oxidase Proteins 0.000 abstract 1
- 102100033220 Xanthine oxidase Human genes 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009086306 | 2009-03-31 | ||
| JP2009279976 | 2009-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2415771E true PT2415771E (pt) | 2013-10-03 |
Family
ID=42828231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107587131T PT2415771E (pt) | 2009-03-31 | 2010-03-30 | Derivado de indolizina e sua utilização para fins médicos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8748452B2 (pt) |
| EP (1) | EP2415771B1 (pt) |
| JP (1) | JP5638513B2 (pt) |
| KR (1) | KR101772963B1 (pt) |
| CN (1) | CN102365281B (pt) |
| AU (1) | AU2010231615B2 (pt) |
| BR (1) | BRPI1013432B1 (pt) |
| CA (1) | CA2755132C (pt) |
| CY (1) | CY1114520T1 (pt) |
| DK (1) | DK2415771T3 (pt) |
| ES (1) | ES2429148T3 (pt) |
| HR (1) | HRP20130846T1 (pt) |
| MX (1) | MX2011010395A (pt) |
| PL (1) | PL2415771T3 (pt) |
| PT (1) | PT2415771E (pt) |
| RU (1) | RU2529868C2 (pt) |
| SI (1) | SI2415771T1 (pt) |
| TW (1) | TWI471325B (pt) |
| WO (1) | WO2010113942A1 (pt) |
| ZA (1) | ZA201107085B (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130099064A (ko) | 2010-09-29 | 2013-09-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | (아자)인돌리진 유도체 및 그 의약용도 |
| NO2686520T3 (pt) | 2011-06-06 | 2018-03-17 | ||
| KR20140060535A (ko) * | 2011-08-24 | 2014-05-20 | 깃세이 야쿠힌 고교 가부시키가이샤 | 축합 헤테로환 유도체 및 그 의약용도 |
| RU2627591C2 (ru) | 2012-10-23 | 2017-08-09 | Тейдзин Фарма Лимитед | Терапевтический или профилактический агент для синдрома распада опухоли |
| WO2014194226A2 (en) | 2013-05-31 | 2014-12-04 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treatment and compositions with xanthine oxidase inhibitors |
| DK3007695T3 (da) | 2013-06-13 | 2024-03-18 | Akebia Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af anæmi |
| PT3105226T (pt) | 2014-02-13 | 2019-11-06 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
| ME03654B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
| TW201613860A (en) | 2014-02-13 | 2016-04-16 | Incyte Corp | Cyclopropylamines as LSD1 inhibitors |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| MX2017009417A (es) | 2015-01-23 | 2017-12-07 | Akebia Therapeutics Inc | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. |
| PT3277270T (pt) | 2015-04-01 | 2021-12-07 | Akebia Therapeutics Inc | Composições e métodos de tratamento de anemia |
| AU2016243939B2 (en) | 2015-04-03 | 2020-09-03 | Incyte Holdings Corporation | Heterocyclic compounds as LSD1 inhibitors |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| US10266496B2 (en) | 2015-09-02 | 2019-04-23 | Sunshine Lake Pharma Co., Ltd. | Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof |
| US10894038B2 (en) * | 2015-12-28 | 2021-01-19 | Shanghai Fochon Pharmaceutical Co. Ltd. | Indolizine derivatives, composition and methods of use |
| AR109452A1 (es) | 2016-04-22 | 2018-12-12 | Incyte Corp | Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento |
| EA038701B1 (ru) * | 2016-09-07 | 2021-10-07 | Хайхэ Биофарма Ко., Лтд. | Пиридо пятичленное ароматическое циклическое соединение, способ его получения и применение |
| MX2020011845A (es) | 2018-05-09 | 2021-01-15 | Akebia Therapeutics Inc | Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico. |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| JP2023052711A (ja) * | 2020-03-04 | 2023-04-12 | 国立研究開発法人理化学研究所 | 化合物を放出する方法 |
| AR126164A1 (es) * | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
| CN115785018A (zh) * | 2022-12-26 | 2023-03-14 | 湖北广济药业股份有限公司 | 一种非布司他脱羧杂质的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ193926A (en) * | 1979-07-06 | 1984-05-31 | Labaz Sanofi Nv | 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines |
| FR2779724B1 (fr) * | 1998-06-10 | 2001-04-20 | Rhone Poulenc Rorer Sa | Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent |
| WO2007043400A1 (ja) * | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
| DE602006018635D1 (de) | 2005-10-07 | 2011-01-13 | Astellas Pharma Inc | Triarylcarbonsäurederivat |
| US8003647B2 (en) | 2007-04-11 | 2011-08-23 | Kissei Pharmaceutical Co., Ltd. | (Aza)indole derivative and use thereof for medical purposes |
| JP5330990B2 (ja) * | 2007-04-11 | 2013-10-30 | キッセイ薬品工業株式会社 | 含窒素複素環化合物およびそれを含有する医薬組成物 |
| EP2133331A4 (en) | 2007-04-11 | 2011-06-22 | Kissei Pharmaceutical | FIVE-GLASS HETEROCYCLIC DERIVATIVE AND ITS USE IN MEDICAL PURPOSES |
-
2010
- 2010-03-30 BR BRPI1013432A patent/BRPI1013432B1/pt not_active IP Right Cessation
- 2010-03-30 HR HRP20130846AT patent/HRP20130846T1/hr unknown
- 2010-03-30 EP EP10758713.1A patent/EP2415771B1/en active Active
- 2010-03-30 PL PL10758713T patent/PL2415771T3/pl unknown
- 2010-03-30 AU AU2010231615A patent/AU2010231615B2/en not_active Ceased
- 2010-03-30 SI SI201030404T patent/SI2415771T1/sl unknown
- 2010-03-30 ES ES10758713T patent/ES2429148T3/es active Active
- 2010-03-30 DK DK10758713.1T patent/DK2415771T3/da active
- 2010-03-30 MX MX2011010395A patent/MX2011010395A/es active IP Right Grant
- 2010-03-30 CA CA2755132A patent/CA2755132C/en not_active Expired - Fee Related
- 2010-03-30 WO PCT/JP2010/055692 patent/WO2010113942A1/ja not_active Ceased
- 2010-03-30 JP JP2011507210A patent/JP5638513B2/ja not_active Expired - Fee Related
- 2010-03-30 RU RU2011143741/04A patent/RU2529868C2/ru not_active IP Right Cessation
- 2010-03-30 PT PT107587131T patent/PT2415771E/pt unknown
- 2010-03-30 KR KR1020117024420A patent/KR101772963B1/ko not_active Expired - Fee Related
- 2010-03-30 US US13/259,621 patent/US8748452B2/en active Active
- 2010-03-30 CN CN201080014876.1A patent/CN102365281B/zh not_active Expired - Fee Related
- 2010-03-31 TW TW99109853A patent/TWI471325B/zh not_active IP Right Cessation
-
2011
- 2011-09-28 ZA ZA2011/07085A patent/ZA201107085B/en unknown
-
2013
- 2013-10-17 CY CY20131100921T patent/CY1114520T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1114520T1 (el) | 2016-10-05 |
| AU2010231615A1 (en) | 2011-11-03 |
| BRPI1013432A2 (pt) | 2016-04-05 |
| EP2415771A1 (en) | 2012-02-08 |
| PL2415771T3 (pl) | 2014-01-31 |
| TWI471325B (zh) | 2015-02-01 |
| KR20110132599A (ko) | 2011-12-08 |
| HRP20130846T1 (hr) | 2013-11-22 |
| RU2011143741A (ru) | 2013-05-10 |
| US8748452B2 (en) | 2014-06-10 |
| HK1165793A1 (en) | 2012-10-12 |
| WO2010113942A1 (ja) | 2010-10-07 |
| ZA201107085B (en) | 2012-12-27 |
| AU2010231615B2 (en) | 2014-05-15 |
| KR101772963B1 (ko) | 2017-08-31 |
| RU2529868C2 (ru) | 2014-10-10 |
| CN102365281A (zh) | 2012-02-29 |
| MX2011010395A (es) | 2011-10-24 |
| CA2755132C (en) | 2018-02-13 |
| CN102365281B (zh) | 2014-11-12 |
| ES2429148T3 (es) | 2013-11-13 |
| BRPI1013432B1 (pt) | 2019-12-17 |
| SI2415771T1 (sl) | 2013-12-31 |
| US20120015972A1 (en) | 2012-01-19 |
| JPWO2010113942A1 (ja) | 2012-10-11 |
| EP2415771A4 (en) | 2012-08-29 |
| CA2755132A1 (en) | 2010-10-07 |
| EP2415771B1 (en) | 2013-07-31 |
| TW201040178A (en) | 2010-11-16 |
| DK2415771T3 (da) | 2013-10-14 |
| JP5638513B2 (ja) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2415771E (pt) | Derivado de indolizina e sua utilização para fins médicos | |
| PT2133332E (pt) | Derivado de (aza)indole e sua utilização para fins médicos | |
| MX2009010491A (es) | Derivado heterociclico de 5 miembros y su uso para propositos medicos. | |
| EA201201663A1 (ru) | Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1 | |
| GEP20156250B (en) | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 | |
| MY155836A (en) | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators | |
| MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
| NO20090166L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| EP2288260A4 (en) | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD | |
| MX336271B (es) | Compuestos de triazolopiridina inhibidores de jak y los metodos. | |
| NO20090755L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| TN2011000053A1 (en) | Organic compounds | |
| NO20090246L (no) | Substituerte isoindoler som bace-inhibitorer og deres anvendelse | |
| PT2192109E (pt) | Derivado de -aminoácido bicíclico | |
| MX2009012168A (es) | Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta. | |
| PT2349261E (pt) | Derivados de pirazolo-piridina como inibidores de nadph-oxidase | |
| GEP20125537B (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| TN2010000293A1 (en) | Thiazole derivatives used as pi 3 kinase inhibitors | |
| MY160357A (en) | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators | |
| NO20091858L (no) | Hydrobenzamid derivater som inhibitorer av HSP90 | |
| WO2011038234A3 (en) | Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions | |
| NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
| NO20083058L (no) | Cykloheksylsulfonamidderivater med H3 reseptor aktivitet | |
| WO2011159124A3 (ko) | Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 | |
| PH12013500644A1 (en) | Co-crystals and salts of ccr3-inhibitors |